Scholarlink

Purpose <p>Thrombectomy (TE) is the standard of care for stroke patients with large vessel occlusion. While TE achieves high recanalization rates, a&#xa0;subset of clots requires three or more thrombectomy maneuvers (“challenging or tough clots”) which is associated with increased complication rates and poor clinical outcome. The underlying biological properties of tough clots are poorly understood, and it remains unclear whether these have distinct structural characteristics or etiology that might contribute to their resistance to TE.</p> Methods <p>We performed a&#xa0;prospective, single-center study which analyzed clot composition in 33&#xa0;consecutive ischemic stroke patients. This included 16&#xa0;tough clots (48%) which were analyzed in a&#xa0;predefined subgroup analysis. Clots were assessed by preinterventional imaging, <i>ex vivo </i>high field MRI (“MR-microscopy”, 9.4 T) and histopathology. Imaging data was correlated with clinical parameters and outcome.</p> Results <p>MR microscopy showed mainly platelet-rich clots (white, 21&#xa0;clots, 64%), whereas mixed (9&#xa0;clots 27%) and red blood cell-rich (3&#xa0;clots, 9%) were less frequent. Tough clots were mostly white (14/16 clots, 87.5%), had increased procedure time and required more maneuvers to achieve recanalization (mean number of maneuvers: white clots: 3.2 ± 1.4, mixed clots: 1.7 ± 0.9, RBC-rich clots 1.3 ± 0.6 passes). Cancer patients undergoing thrombectomy and cardiac patients with periprocedural emboli often exhibited tough clots (63% and 67% respectively). TE patients with concomitant cancer had inferior outcome both at discharge and at 90&#xa0;days follow-up.</p> Conclusion <p>Tough clots are platelet-rich, show an association with underlying comorbidities and are associated with malignancies. This highlights the combined influence of clot composition and pre-existing comorbidities on thrombectomy success and supports the need for individualized stroke management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiparametric Characterization of Tough Clots Following Stroke Thrombectomy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Kianush Karimian-Jazi,
  • Vasileios Kapralos,
  • Daniel Schwarz,
  • Dominik Vollherbst,
  • Manuel Fischer,
  • Volker Sturm,
  • Niclas Schmitt,
  • Tim Hilgenfeld,
  • Christian Herweh,
  • Fabian Preisner,
  • Christoph Mooshage,
  • Sophia Hohenstatt,
  • Stefan Hamelmann,
  • Felix Hinz,
  • Felix Sahm,
  • Sabine Heiland,
  • Wolfgang Wick,
  • Peter Ringleb,
  • Martin Bendszus,
  • Markus Möhlenbruch,
  • Michael Breckwoldt

摘要

Purpose

Thrombectomy (TE) is the standard of care for stroke patients with large vessel occlusion. While TE achieves high recanalization rates, a subset of clots requires three or more thrombectomy maneuvers (“challenging or tough clots”) which is associated with increased complication rates and poor clinical outcome. The underlying biological properties of tough clots are poorly understood, and it remains unclear whether these have distinct structural characteristics or etiology that might contribute to their resistance to TE.

Methods

We performed a prospective, single-center study which analyzed clot composition in 33 consecutive ischemic stroke patients. This included 16 tough clots (48%) which were analyzed in a predefined subgroup analysis. Clots were assessed by preinterventional imaging, ex vivo high field MRI (“MR-microscopy”, 9.4 T) and histopathology. Imaging data was correlated with clinical parameters and outcome.

Results

MR microscopy showed mainly platelet-rich clots (white, 21 clots, 64%), whereas mixed (9 clots 27%) and red blood cell-rich (3 clots, 9%) were less frequent. Tough clots were mostly white (14/16 clots, 87.5%), had increased procedure time and required more maneuvers to achieve recanalization (mean number of maneuvers: white clots: 3.2 ± 1.4, mixed clots: 1.7 ± 0.9, RBC-rich clots 1.3 ± 0.6 passes). Cancer patients undergoing thrombectomy and cardiac patients with periprocedural emboli often exhibited tough clots (63% and 67% respectively). TE patients with concomitant cancer had inferior outcome both at discharge and at 90 days follow-up.

Conclusion

Tough clots are platelet-rich, show an association with underlying comorbidities and are associated with malignancies. This highlights the combined influence of clot composition and pre-existing comorbidities on thrombectomy success and supports the need for individualized stroke management.